CY1120686T1 - ANTIBODIES SPECIFIC FOR HUMAN ISLIDIC STORAGE POLYPEPTID (ISAPS) AND THEIR USES - Google Patents

ANTIBODIES SPECIFIC FOR HUMAN ISLIDIC STORAGE POLYPEPTID (ISAPS) AND THEIR USES

Info

Publication number
CY1120686T1
CY1120686T1 CY181100965T CY181100965T CY1120686T1 CY 1120686 T1 CY1120686 T1 CY 1120686T1 CY 181100965 T CY181100965 T CY 181100965T CY 181100965 T CY181100965 T CY 181100965T CY 1120686 T1 CY1120686 T1 CY 1120686T1
Authority
CY
Cyprus
Prior art keywords
antibodies specific
human
islidic
isaps
polypeptid
Prior art date
Application number
CY181100965T
Other languages
Greek (el)
Inventor
Jan Grimm
Fabrice Heitz
Feng Chen
Ioana Combaluzier
Original Assignee
Neurimmune Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/068907 external-priority patent/WO2014041069A1/en
Application filed by Neurimmune Holding Ag filed Critical Neurimmune Holding Ag
Publication of CY1120686T1 publication Critical patent/CY1120686T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχονται νέα ανθρώπινα, ειδικά για το πολυπεπτίδιο του αμυλοειδούς των νησιδίων επίσης γνωστό ως αμυλίνη και ΙΑΡΡ και prolAPP αντίστοιχα αντισώματα όπως επίσης θραύσματα, παράγωγα και παραλλαγές αυτών όπως επίσης μέθοδοι σχετικές με αυτά. Προσδιορισμοί, κιτ και στερεοί φορείς ειδικοί για αντισώματα ειδικά για ΙΑΡΡ και prolAPP παρέχονται επίσης. Το αντίσωμα, αλυσίδα(ες) ανοσοσφαιρίνης όπως επίσης θραύσματα δέσμευσης, παράγωγα και παραλλαγές αυτών μπορούν να χρησιμοποιηθούν σε φαρμακευτικές και διαγνωστικές συνθέσεις για ΙΑΡΡ και prolAPP στοχευόμενη ανοσοθεραπεία και διαγνωστικές μεθόδους αντίστοιχα.New human, especially for the islet amyloid polypeptide also known as amylin and IAPP and prolAPP corresponding antibodies as well as fragments, derivatives and variants thereof as well as related methods are provided. Assays, kits and solid carriers specific for antibodies specific for IAPP and prolAPP are also provided. The antibody, immunoglobulin chain (s) as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and prolAPP targeted immunotherapy and diagnostic methods respectively.

CY181100965T 2012-09-12 2018-09-18 ANTIBODIES SPECIFIC FOR HUMAN ISLIDIC STORAGE POLYPEPTID (ISAPS) AND THEIR USES CY1120686T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261700110P 2012-09-12 2012-09-12
EP12184134 2012-09-12
PCT/EP2013/068907 WO2014041069A1 (en) 2012-09-12 2013-09-12 Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof
EP13765328.3A EP2895512B1 (en) 2012-09-12 2013-09-12 Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CY1120686T1 true CY1120686T1 (en) 2019-12-11

Family

ID=65859688

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100965T CY1120686T1 (en) 2012-09-12 2018-09-18 ANTIBODIES SPECIFIC FOR HUMAN ISLIDIC STORAGE POLYPEPTID (ISAPS) AND THEIR USES

Country Status (5)

Country Link
BR (1) BR112015005549B1 (en)
CY (1) CY1120686T1 (en)
HU (1) HUE040354T2 (en)
IL (1) IL237719B (en)
PT (1) PT2895512T (en)

Also Published As

Publication number Publication date
PT2895512T (en) 2018-10-16
IL237719B (en) 2020-06-30
IL237719A0 (en) 2015-05-31
BR112015005549A2 (en) 2020-09-15
HUE040354T2 (en) 2019-03-28
BR112015005549B1 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
CY1123518T1 (en) HUMAN ENANTI-TAU ANTIBODIES
CY1120951T1 (en) HUMAN ANTIBODIES ENANTI-TAU
CY1121536T1 (en) HUMAN ANTIBODIES AGAINST ALPHA-SYNUCLEIN
CY1122210T1 (en) HUMAN ANTI-SOD1 ANTIBODIES
CY1121392T1 (en) COMBINATION MOLECULES AGAINST ALPHA-SYNUCLEIN
CY1119647T1 (en) ALUMINUM ACCESSORIES AND ACCESSORIES FOR ACCESSORIES
CY1120471T1 (en) Anti-CD70 antibodies
CO2018005436A2 (en) Antibodies and antibody fragments for site-specific conjugation
EA201590459A1 (en) SPECIFIC ANTIBODIES TO ISLAND AMYLOID HUMAN POLYPEPTIDE (HIAPP) AND THEIR APPLICATION
BR112014028785A2 (en) st2 antigen binding proteins
MX2018008680A (en) Tdp-43 specific binding molecules.
EA201491599A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
CY1115091T1 (en) SPECIFIC PROTECTION ANTIGEN PROTECTION PROTEINS
TR201910348T4 (en) Antibodies to matrix metalloproteinase 9.
BR112014010532A2 (en) antibody and methods for selective inhibition of t-cell responses
TN2014000120A1 (en) Cd27l antigen binding proteins
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
AR080466A1 (en) SELECTIVE ENRICHMENT OF ANTIBODIES
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.
MA38165A1 (en) Her3 antigen binding proteins binding to her3 beta hairpin
EA201790816A1 (en) ANTIBODIES THAT ARE ASSOCIATED WITH CCR6 AND APPLICATION OPTIONS FOR THE INDICATED ANTIBODIES
BR112018073660A2 (en) anti-factor ix padua antibodies
BR112015017981A2 (en) human antibody specific for human metapneumovirus, or antigen binding fragment thereof, its use and pharmaceutical composition comprising it, as well as isolated nucleic acid, recombinant expression vector and host cell
CY1120686T1 (en) ANTIBODIES SPECIFIC FOR HUMAN ISLIDIC STORAGE POLYPEPTID (ISAPS) AND THEIR USES
AR124605A2 (en) ANTI-IL-36R ANTIBODIES